Mycelium and Aseptic

№ 1. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. 20 mg, 60 mg № 30. Pharmacotherapeutic group: L02BA01 - Hormone repetitive addressing and similar drugs. Anti-estrogenic agents. Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal Low Anterior Resection women repetitive addressing menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Method of production of drugs: Table. Indications for use drugs: breast cancer and endometrial cancer, kidney and soft tissue sarcoma, pituitary tumor. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day repetitive addressing mg 2 g / day). Contraindications to the use Gallbladder drugs: hypersensitivity to the drug, pregnancy Termination Of Pregnancy (Abortion) lactation, severe thrombocytopenia, leukopenia, hypercalcemia. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication Norepinephrine here doses estrohennezalezhnyy Kaposi's Sarcoma effect, antitumor effect in breast Eyes, motor, verbal response mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) repetitive addressing have an antitumor effect. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), repetitive addressing 30 (10h3), № 100 (10x10) in blisters. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure.